Inventor
Mark D. Wittman
Inventor
Wallingford, CT, US
Overview
Patents· 33 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds39%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
A61KPreparations for medical, dental or toiletry purposes11%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium8%
Y02ATechnologies for adaptation to climate change5%
C07CAcyclic or carbocyclic compounds4%
H10WGeneric packages, interconnections, connectors or other constructional details of devices covered by class h104%
C07HSugars3%
PatentTitleYear
9,956,220Imidazo-pyridazine derivatives as casein kinase 1 d/[?] inhibitors20189,598,423'Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors'20179,556,179'Substituted imidazoles as casein kinase 1 D/E inhibitors'20179,475,817'Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors'20169,273,058'Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors'20168,592,579'Pyrrolotriazine kinase inhibitors'20138,415,340'Triazine kinase inhibitors'20138,343,999'Thiazolyl compounds useful as kinase inhibitors'20138,263,765'Pyrrolotriazine kinase inhibitors'20128,198,438'Pyrrolotriazine kinase inhibitors'20128,148,400'Thiazolyl compounds useful as kinase inhibitors'20127,879,855'Pyrrolotriazine kinase inhibitors'20117,534,792'Pyrrolotriazine kinase inhibitors'20097,470,696'Tyrosine kinase inhibitors'20087,312,215'Benzimidazole C-2 heterocycles as kinase inhibitors'20077,232,826'Tyrosine kinase inhibitors'20077,223,757'Tyrosine kinase inhibitors'20077,189,716'Tyrosine kinase inhibitors'20077,081,454'Tyrosine kinase inhibitors'20066,455,575'Phosphonooxymethyl ethers of taxane derivatives'20026,362,217'Taxane anticancer agents'20026,201,140'7-0-ethers of taxane derivatives'20015,977,386'6-thio-substituted paclitaxels'19995,912,264'6-halo-or nitrate-substituted paclitaxels'19995,646,176'Phosphonooxymethyl ethers of taxane derivatives'19975,489,589'Amino acid derivatives of paclitaxel'19965,478,854'Deoxy taxols'19955,412,082'Conversion of amines to hydroxylamines'19955,395,849'Hybrid antitumor compounds containing a cyclic enediyne and a DNA-binder'19955,318,989'Cytotoxic bicyclo [7.3.1.]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof'19945,278,301'Route to glycals in the allal and gulal series'19945,198,560'Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof'19935,104,982'Route to glycals in the allal and gulal series'1992Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1992–1995Patents assigned to UNIV YALE (3)· patent assignee history
1992–1995Based in Hamden, CT, US· patent location history
1993–2018Patents assigned to BRISTOL MYERS SQUIBB CO (30)· patent assignee history
1993–2002Based in Cheshire, CT, US· patent location history
2002–2018Based in Wallingford, CT, US· patent location history
2007Based in Waliingford, CT, US· patent location history
2012–2013Patents assigned to WITTMAN MARK D (6)· patent assignee history
2012–2013Patents assigned to LANGLEY DAVID R (4)· patent assignee history
2012–2013Patents assigned to SANG XIAOPENG (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 30 | 1993–2018 |
| WITTMAN MARK Dself | 6 | 2012–2013 |
| LANGLEY DAVID R | 4 | 2012–2013 |
| SANG XIAOPENG | 3 | 2012–2013 |
| UNIV YALE | 3 | 1992–1995 |
Locations
| Location | Patents | Span |
|---|---|---|
| Wallingford, CT, US | 19 | 2002–2018 |
| Cheshire, CT, US | 10 | 1993–2002 |
| Hamden, CT, US | 3 | 1992–1995 |
| Waliingford, CT, US | 1 | 2007 |